Effects of Romosozumab on Bone Density in Women With Anorexia Nervosa

Model scores of the 29,894 trials active now.

Model score 13% for any early termination, 11% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 12% of the time (146 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2025-11-17. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Accepts healthy volunteers: No (raises risk) · Who can join
• Minimum age: 20 (lowers risk) · Who can join
• Responsible party: sponsor investigator (raises risk) · Design
• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: bonewomenmonthsplacebodiabetes
  Phrases that lowered it: participantsopen labelinvestigate thereceivesafety of
• Phase: 3 (lowers risk) · Design
• Design: parallel (raises risk) · Design
• Sponsor's past termination rate: no earlier finished trials (lowers risk) · Sponsor's track record
• Drug's FAERS reports with a death: 15.1% (lowers risk) · Drug's FDA history
• Has a data monitoring committee: Yes (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 0 (raises risk) · Sponsor's track record
• Disease area, psychiatry: Yes (raises risk) · Disease area
• Blinding: double (raises risk) · Design
• Number of arms: 2 (raises risk) · Design
• Maximum age: 60 (lowers risk) · Who can join
• Collaborators: 1 (raises risk) · Design
• Disease area, neurology: No (lowers risk) · Disease area

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Effects of Denosumab on Bone Mineral Density in Women With Anorexia Nervosa: A Pilot Study NCT03292146 · started 2017 · scored riskier than 36% of active trials completed
• A Study to Test the Efficacy, Safety and Tolerability of Romosozumab Treatment in Postmenopausal Chinese Women With Osteoporosis NCT05067335 · started 2021 · scored riskier than 72% of active trials completed
• Romosozumab (AMG 785) in Postmenopausal Women With Low Bone Mineral Density NCT00896532 · started 2009 · scored riskier than 21% of active trials completed
• An Open-label Study to Evaluate the Effect of Treatment With Romosozumab or Teriparatide in Postmenopausal Women NCT01796301 · started 2013 · scored riskier than 12% of active trials completed
• A Study to Evaluate the Safety and Efficacy of Denosumab and Ibandronate in Postmenopausal Women Sub-Optimally Treated With Daily or Weekly Bisphosphonates NCT00936897 · started 2009 · scored riskier than 40% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.